(IMMX) Is A Tiny Float Nasdaq Biopharma Idea With 4 Incredible Potential Catalysts (Big FDA News)

SmallCapFirm

(IMMX) Is A Tiny Float Nasdaq Biopharma Idea With 4 Incredible Potential Catalysts (Big FDA News)

Yahoo Finance Reports IMMX To Have A Float Of 1.29Mn!

January 3rd

SCF Readers,

Welcome to 2022! Let's get it kicked off the right way.

Over the past few weeks, I brought some brain-bustin' runners to your attention. Check them out:

#1. On 12/27, I brought BTCY to your attention. That morning it opened at $4.10 and blazed its way to a high of $5.30 one day later.

That $1.00+ run resulted in a move of approximately 29%.

#2. We watched STAL throw down on 12/17 when it opened at $1.70 and slashed its way to a high of $2.30 on the day.

That $.60 move proved STAL a 35% intraday champ.

#3. Sandwiched in between was BWTX, one of our biggest breakout alerts ever. Running an almost impossible $.80+ from an open of $.0094 to a high of $.8099, BWTX set its chart on fire.

Overall, BWTX ran an earth-shattering 8,515% (approx.) intraday.

But like I said, it's 2022 now. It's time to go big or go home.

I've uncovered a new Nasdaq profile you've got to get on your radar quickly.

For Monday, January 3rd, Nasdaq biopharma company Immix Biopharma, Inc. (IMMX) requires immediate attention.

ImmixBio™ is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases.

Their proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific™ Platform produces dr-ugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines.

The company's TME Normalization™ Technology allows their dr-ug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME.

They've uncovered fundamental biological systems that link oncology and immuno-dysregulated diseases. In addition to oncology, the company's pipeline includes Tissue-Specific Biologic™ candidates to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

*IMMX's Insanely Huge Market Opportunities* (1)

STS is a rare cancer that begins in the tissues that connect, support, and surround the body structures. These tissues include muscle, fat, blood vessels, tendons, nerves and joint linings. The global STS market is estimated to reach approximately $6.5Bn by 2030 from the estimated $2.9Bn in 2019. Globally, there are roughly 116,000 new cases of STSs each year, of which 21,500 are in the European Union and 40,500 are in China. According to the American Cancer Society, there were roughly 13,000 new cases of STS in the United States during 2020. Approximately 160,000 people live with soft tissue cancers in the United States.

Colorectal cancers are cancers that arise from the colon, rectum and anus. The colorectal cancer market is estimated to reach approximately $31.2Bn by 2025 from the estimated $26.3Bn in 2019. According to the American Cancer Society, there were roughly 149,500 new cases of colorectal cancer in the United States. Globally, there are roughly 1,930,000 new cases of colorectal cancer each year, of which 519,500 are in Europe, 148,500 are in Japan, 20,500 are in Australia and New Zealand, and 555,000 are in China.

Inflammatory bowel disease is a complex disease with many contributing factors, primarily caused by an overactive immune system. Ulcerative colitis and Crohn’s disease are two of the most common forms of inflammatory bowel disease. The inflammatory bowel disease market is expected to reach $21.4Bn by 2024 from the existing $18.4Bn in 2019. Inflammatory bowel disease is estimated to affect over 2,000,000 people in the United States and over 5,000,000 people globally.

-----

IMMX Could Have New First-Line Therapy for STS

At the moment, current cancer treatment approaches are generally either cytotoxic chemotherapies or focus on targeting one single receptor or one single mutation, which limits their ability to counter an evolvable tumor and its micro-environment. (2)

With its Tissue-Specific Therapeutic IMX-110 treatment, the company believes it may have first-line therapy for STS and multiple other solid tumors, improving tolerability and progression free survival, while providing an alternative to conventional doxorubicin, a current first-line therapy initially approved for medical use in the United States in 1974. (1)

Given IMX-110’s novel feature of co-delivery of a resistance-suppressing poly-kinase inhibitor with an apoptosis inducer, the company believes IMX-110 can be used for treatment-resistant STS and other advanced, treatment-resistant cancers.

Plus, IMX-110 represents a dramatic shift away from a focus on cytotoxic or targeted therapies alone which, while producing initial tumor shrinkage, simultaneously activate pathways that lead to cancer relapse and treatment resistance.

Check out the full company presentation here.

-----

Right now, IMMX has several potential catalysts that could fuel this profile towards a vertical move near term. And none may be more important than this one...

IMMX No 1. Potential Catalyst - U.S. FDA Grants Orphan Dr-ug Designation

ImmixBio Announces FDA Orphan Dr-ug Designation for IMX-110 for the Treatment of Soft Tissue Sarcoma

LOS ANGELES, Sept. 30, 2021 /PRNewswire/ — Immix Biopharma, Inc. (“ImmixBio”), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)™ for oncology and inflammation, today announced that the U.S. Food and Dr-ug Administration (FDA) has granted orphan dr-ug designation (ODD) to IMX-110 for the treatment of soft tissue sarcoma.

The FDA’s Office of Orphan Products Development grants orphan designation status to dr-ugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Dr-ug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to 7 years of market exclusivity in the U.S. upon regulatory approval.

“We are pleased to receive FDA’s orphan dr-ug designation in soft tissue sarcoma for IMX-110, the first clinical-stage product of our SMARxT Tissue-Specific Platform,” said Ilya Rachman MD PhD, ImmixBio Founder & CEO. “We are thrilled to potentially contribute to expanding therapeutic options for oncology patients, beginning with soft tissue sarcoma.”

Gabriel Morris, ImmixBio Chief Financial Officer, added: “Orphan dr-ug designation for IMX-110 represents a substantial value creating step along our path of building a strong, independent biopharmaceutical organization.”

Read the full article here.

-----

IMMX No 2. Potential Catalyst - A Crazy Low Float

According to the Yahoo Finance website, IMMX has a tiny float.

The website reports this profile to have approximately 1.29Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, other potential catalysts could help spark a vertical move in the short-term.

-----

IMMX No 3. Potential Catalyst - IPO And Joining The NasdaqCM

Immix Biopharma, Inc. Announces Closing of Initial Public Offering

LOS ANGELES, CA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the closing of its initial public offering of 4,200,000 shares of its common st-ock at a public offering price of $5.00 per share, for gross proceeds of $21Mn, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 630,000 shares of common st-ock at the initial public offering price, less the underwriting discount, to cover over-allotments.

The shares began trading on the Nasdaq Capital Market on December 16, 2021 under the ticker symbol “IMMX.”

ThinkEquity acted as sole book-running manager for the offering.

The Company intends to use the net proceeds from the offering to fund a planned IMX-110 Phase 2a clinical trial in soft tissue sarcoma and IMX-110 + tislelizumab Phase 1b combination trial, for IND-enabling studies for IMX-111 (colorectal cancer) and IMX-120 (inflammatory bowel disease), and for working capital and other general corporate purposes.

[...]

Read the full article here.

-----

IMMX No 4. Potential Catalyst - Company Nears Phase 2a Trials

The company plans to treat even more STS patients in a Phase 2a trial with IMX-110 as a first-line therapy. The rationale for that includes: (2)

Encouraging clinical trial and tolerability data in its IMX-110 Phase 1b escalation trial
Precedent US FDA clinical trial design for a first line treatment
Interest from leading STS principal investigators

Even better, IMX-110 represents a paradigm shift away from a focus on cytotoxic or targeted therapies alone which, while producing initial tumor shrinkage, simultaneously activate pathways that lead to cancer relapse and treatment resistance.

More details here.

-----

IMMX Complete Recap - 4 Potential Catalysts Lead The Way

No 1. - U.S. FDA Grants Orphan Dr-ug Designation

No 2. - A Crazy Low Float

No 3. - IPO And Joining The NasdaqCM

No 4. - Company Nears Phase 2a Trials

-----

Coverage is officially initiated on IMMX. When you have time later, do this:

Get IMMX on your radar now.

Sincerely,

Axel Adams

Editor, SCF

Source 1
Source 2

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SmallCapFirm and StockNewsWire LLC, SmallCapFirm has been hired for a period beginning on 1/3/22 and ending on 1/4/22 to publicly disseminate information about (IMMX) via Website, Email and SMS. We have been paid fifteen thousand USD via bank wire transfer. We own zero shares of (IMMX). This fifteen thousand USD may be used for future marketing and advertising on this company or other companies on an ongoing basis. All companies will be disclosed. An owner of StockNewsWire LLC owns an interest in SmallCapFirm (SCF). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 1/3/22 and ending on 1/4/22 to publicly disseminate information about (IMMX) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (IMMX). This eighty-two thousand five hundred USD may be used for future marketing and advertising on this company or other companies on an ongoing basis. All companies will be disclosed. Pursuant to an agreement between SmallCapFirm and StockNewsWire LLC, SmallCapFirm has been hired for a period beginning on 9/15/21 and ending on 9/16/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We have been paid fifteen thousand USD via bank wire transfer. We own zero shares of (BTCY). An owner of StockNewsWire LLC owns an interest in SmallCapFirm (SCF). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 9/15/21 and ending on 9/16/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid sixty-seven thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between SmallCapFirm and StockNewsWire LLC, SmallCapFirm has been hired for a period beginning on 10/7/21 and ending on 10/8/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We have been paid two thousand five hundred USD via bank wire transfer. We own zero shares of (BTCY). An owner of StockNewsWire LLC owns an interest in SmallCapFirm (SCF). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 10/7/21 and ending on 10/8/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid fifteen thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between SmallCapFirm and StockNewsWire LLC, SmallCapFirm has been hired for a one day period beginning on 10/29/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We have been paid two thousand five hundred USD via bank wire transfer. We own zero shares of (BTCY). An owner of StockNewsWire LLC owns an interest in SmallCapFirm (SCF). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a one day period beginning on 10/29/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid ten thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between SmallCapFirm and StockNewsWire LLC, SmallCapFirm has been hired for a period beginning on 12/27/21 and ending on 12/28/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We have been paid five thousand USD via bank wire transfer. We own zero shares of (BTCY). To date we have been compensated a total of twenty-five thousand USD via bank wire transfer to disseminate information about (BTCY). An owner of StockNewsWire LLC owns an interest in SmallCapFirm (SCF). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 12/27/21 and ending on 12/28/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid twenty-five thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). To date we have been compensated a total of one hundred and seventeen thousand five hundred USD via bank wire transfer to disseminate information about (BTCY). Pursuant to an agreement between SmallCapFirm and StockNewsWire LLC, SmallCapFirm was hired for a period beginning on 12/16/21 and ending on 12/17/21 to publicly disseminate information about (STAL) via Website, Email and SMS. We were paid five thousand USD via bank wire transfer. We own zero shares of (STAL). An owner of StockNewsWire LLC owns an interest in SmallCapFirm. Pursuant to an agreement between StockNewsWire, LLC, and Awareness Consulting Network, LLC, StockWireNews was hired for a period beginning on 12/16/21 and ending on 12/17/21 to publicly disseminate information about (STAL) via Website, Email and SMS. We were paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (STAL). We were not compensated for our profile on (BWTX). We own zero shares of (BWTX).